OcuTerra Completes Enrollment in Phase 2 DR:EAM Clinical Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathy

TAGGED : health

DocGo to Announce Third Quarter 2023 Results on Monday, November 6, 2023

October 23, 2023

NEW YORK--(BUSINESS WIRE)--Oct 23, 2023--<a ...

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

October 23, 2023

TORONTO & LONDON--(BUSINESS WIRE)--Oct 23, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (鈥� Cybin 鈥�, or the 鈥� Company 鈥�) and Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (鈥� Small ...

Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor Presented at 2023 AACR-NCI-EORTC International Conference

October 23, 2023

SAN FRANCISCO--(BUSINESS WIRE)--Oct 23, 2023--Circle Pharma, in collaboration with the laboratory of Violeta Serra, Ph.D., at Vall d鈥橦ebron Institute of Oncology (VHIO) in Barcelona, Spain, recently unveiled preclinical data demonstrating the efficacy of Circle蘑菇视频 oral Cyclin A/B inhibitor ...

Aviceda Completes Enrollment in Part 1 of the SIGLEC Phase 2/3 U.S. Clinical Trial; Initiation of Part 2 Imminent

October 23, 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 23, 2023--<a ...

Bicara Therapeutics Presents Updated Interim Data from Ongoing Phase 1/1b Study of BCA101 in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) at ESMO Congress 2023

October 23, 2023

BOSTON--(BUSINESS WIRE)--Oct 23, 2023--Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the presentation of updated, positive interim data from its ongoing, open-label Phase 1/1b dose ...

Darbepoetin Alfa (Aranesp) Global Market Research Report 2023 – ResearchAndMarkets.com

October 23, 2023

DUBLIN--(BUSINESS WIRE)--Oct 23, 2023--The <a ...